Paying for Cures research, recommendations, and tools
The FoCUS consortium has been working since 2016 to identify challenges and design solutions for financing innovative cell and gene therapies, involving the perspectives of diverse system stakeholders.
Paying for Cures Toolkit
FoCUS Consortium research, findings, and interactive worksheets, organized to help you explore Precision Financing Strategies for your organization.
Precision Financing Strategies
This comprehensive white paper lays out the practices and tools that can help make durable therapies sustainable by the healthcare system.
Six suggestions where we can evolve public policy to make the US healthcare financing and reimbursement system ready for innovative therapies
C. Young; C. Quinn; M. Trusheim. Durable cell and gene therapy potential patient and financial impact: US projections of product approvals, patients treated, and product revenues. Drug Discovery Today (2021). DOI: 10.1016/j.drudis.2021.09.001
Ivica NA, Young CM. Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997–2020). Healthcare. 2021; 9(8):1062. https://doi.org/10.3390/healthcare9081062
J.F. Barlow; M.W. Courtney; M. Trusheim. Payer Perspectives on Gene Therapy Reimbursement. Pharmaceutical Executive, 04/2020
J.F. Barlow; M.W. Courtney; M. Trusheim. Payer Perspectives on Reimbursement of One-Time High-Cost Durable Therapies. Pharmaceutical Executive, 01/09/2020
J.F. Barlow; M. Yang; R. Teagarden. Are Payers Ready, Willing, and Able to Provide Access to New Durable Gene Therapies? Value in Health, 06/2019, 10.1016/j.jval.2018.12.004
J. Barlow; R. Teagarden; M. Trusheim. Precision Financing of Durable, Potentially Curative Therapies. Pharmaceutical Executive, 01/2019
M.R. Trusheim; W.M. Cassidy; P.B. Bach. Alternative State-Level Financing for Hepatitis C Treatment—The "Netflix Model" JAMA, 10/29/2018, 10.1001
D. Han; D.S. Mytelka; G.L. Warren; M. Ciarametaro; M. Trusheim. Improving Management of Gene and Cell Therapies: The Orphan Reinsurer and Benefit Manager (ORBM). PharmaExec.com, 2018
M.R. Trusheim; A.A. Shrier; Z. Antonijevic; R.A. Beckman; R.K. Campbell; C. Chen; K.T. Flaherty; J. Loewy; D. Lacombe; S. Madhavan; H.P. Selker; L.J. Esserman. PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms. Clinical Pharmacology & Therapeutics, 2016, 10.1002/cpt.514
R. Teagarden; T.F. Unger; G. Hirsch. Access and availability of orphan drugs in the United States: advances or cruel hoaxes? Expert Opinion on Orphan Drugs, 2014, 10.1517/21678707.2014.947265
We want to know what works for you, and what doesn't. Please share your thoughts with us!
Subscribe to news
Join our mailing list to keep up to date on Paying for Cures news and events.